Search

everythinglearnresearchcommunity

for

Search:↓

A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.

A user is concerned about using Alpicort, which contains Prednisolone and Salicylic Acid, for male pattern baldness. They are unsure if it will help or worsen their condition and are seeking advice.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

Bimatoprost is discussed for hair and eyelash growth, with users confirming its legitimacy and availability from Indian pharmacies. It is noted that the common concentration may not be effective for significant scalp hair regrowth unless mixed with Minoxidil.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

A 29-year-old male is considering treatments for hair loss, including Minoxidil, Finasteride, microneedling, or a hair transplant, and is concerned about potential hair loss due to military service. He is currently at Norwood 2 and has a family history of hair loss.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.

The user is unsure if their hair appears fuller due to a haircut or actual regrowth, but believes there is increased density and small new hairs. They are using 1 mg finasteride daily, 2.5 mg minoxidil daily, and Nizoral frequently for hair loss treatment.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.